Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.99 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.86 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.86 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.86 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.86 |
| ▸ | STK10 | O94804 | 1/20 | 0.86 |
| ▸ | ABL1 | P00519 | 1/20 | 0.86 |
| ▸ | INSR | P06213 | 1/20 | 0.86 |
| ▸ | RET | P07949 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.86 |
| ▸ | SRC | P12931 | 1/20 | 0.86 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.86 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.86 |
| ▸ | CDK2 | P24941 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL571898 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29356338 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL30680457 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4097293 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL15408126 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL93590 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29866632 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL31732815 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL1374543 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL1651711 | 0.95 | EGFR (0.91) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357769-B2 | Drug combinations for reducing cell viability and/or cell proliferation | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | claimed |
| EP-3454898-A1 | DRUG COMBINATIONS FOR REDUCING CELL VIABILITY AND/OR CELL PROLIFERATION | Eisai R&D Management Co., Ltd. (JP) | 2019-03-20 | — | — | EP | claimed |
| WO-2017196854-A1 | DRUG COMBINATIONS FOR REDUCING CELL VIABILITY AND/OR CELL PROLIFERATION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-11-16 | — | — | WO | claimed |
| EP-2572199-B1 | COMBINATION | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | claimed |
| EP-1871347-B1 | PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2016-08-03 | — | — | EP | claimed |
| EP-2571358-B1 | COMBINATION THERAPY FOR TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | claimed |
| EP-2400033-B1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORP (JP) | 2013-02-20 | — | — | EP | claimed |
| US-12139549-B2 | Material and methods for treating or preventing HER-3 associated diseases | DAIICHI SANKYO EUROPE GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-11857624-B2 | Cancer therapeutic methods utilizing OPCML fragment | PAPYRUS THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11357769-B2 | Drug combinations for reducing cell viability and/or cell proliferation | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| EP-3454898-B1 | DRUG COMBINATIONS FOR REDUCING CELL VIABILITY AND/OR CELL PROLIFERATION | EISAI R&D MAN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-20210196680-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | Piramal Enterprises Limited (IN) | 2021-07-01 | — | — | US | disclosed |
| US-10980776-B2 | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | Piramal Enterprises Limited (IN) | 2021-04-20 | — | — | US | disclosed |
| EP-2499162-A2 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | U3 Pharma GmbH (DE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012018404-A2 | USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT | U3 PHARMA GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-20110300132-A1 | 4-AMINOQUINAZOLINE PRODRUGS | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | LEO OSPREY LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| EP-1294715-B1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-7157466-B2 | Quinazoline ditosylate salt compounds | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-02 | — | — | US | disclosed |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | NOVARTIS AG (CH) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357769-B2 | Drug combinations for reducing cell viability and/or cell proliferation | FGFR4, ERBB4, FGFR3 | EGFR 4/4885ERBB2 11/4885ABCB11 1615/4885 |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABCB11 1630/4885 |
| US-10980776-B2 | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | CDK1, CDK4, CDK11B | EGFR 38/4885ERBB2 92/4885ABCB11 599/4885 |
| US-20110300132-A1 | 4-AMINOQUINAZOLINE PRODRUGS | ERBB2, ERBB4, ERBB3 | EGFR 4/4885ERBB2 1/4885ABCB11 455/4885 |
| US-20210196680-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | CDK1, CDK4, CDK11B | EGFR 38/4885ERBB2 92/4885ABCB11 599/4885 |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABCB11 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.